Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors

Luigi Maresca, Mariantonietta D'Agostino, Luigi Castaldo, Alessandra Vitelli, Maria Mancini, Giorgio Torella, Rosa Lucci, Giovanna Albano, Domenico Del Forno, Matteo Ferro, Vincenzo Altieri, Francesco Giallauria, Carlo Vigorito

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase- 5 (PDE-5) inhibitors. L. Maresca, M. D'Agostino, L. Castaldo, A. Vitelli, M. Mancini, G. Torella, R. Lucci, G. Albano, D. Del Forno, M. Ferro, V. Altieri, F. Giallauria, C. Vigorito. Introduction. Erectile dysfunction (ED) affects about 50% of males aged 40-70 years old. ED shares with atherosclerotic disease several common risk factors; therefore, it may be considered a surrogate marker of atherosclerosis. Sincephosphodiesterase-5 inhibitors are well known pharmacologic agents capable of significant improvement in ED, we designed this study to evaluate whether exercise training is of added value in patients with ED who are already on PDE-5 inhibitors. Methods. We recruited 20 male patients affected by ED with metabolic syndrome.At baseline, all patients underwent Cardio-Pulmonary Exercise Testing (CPET) and the International Index of Erectile Function (IIEF) test.After the initial evaluation, patients were subdivided into two groups: tadalafil group (group T, n=10), who were maintained only on tadalafil therapy, and a tadalafil/exercise training group (T/E group, n=10)who continued tadalafil but in addition underwent a2-month structured exercise training program. Results. Basal anthropometric characteristics of study population showed no significant differences. Although bothgroups showed at 2 months an improvement of the IIEF score, thiswas more evident in the T/E group (T group: 11.2 vs 14.2, P=0.02; T/E group: 10.8 vs 20.1, P2peak) only in the T/E group patients (T group: 13.63±2.03 vs 14.24±2.98 mL/kg/min; P=0.521; T/E group: 13.41±2.97 vs 16.58±3.17 mL/kg/min; P=0.006). A significant correlation was found between the changes in VO2peak and the modifications in IIEF score (r=0.575; P=0.001). Conclusion. Exercise training in ED patients treated with PDE-5 inhibitors is of added valuesincefurther improves ED, as evaluated by IIEF score, and increases functional capacity.

Original languageEnglish
Pages (from-to)177-183
Number of pages7
JournalMonaldi Archives for Chest Disease - Cardiac Series
Volume80
Issue number4
Publication statusPublished - Dec 1 2013

Fingerprint

Phosphodiesterase 5 Inhibitors
Erectile Dysfunction
Exercise
Population Characteristics
Atherosclerosis
Biomarkers
Education
Lung
Tadalafil

Keywords

  • Erectile dysfunction
  • Erectile dysfunction therapy
  • Exercise training
  • Metabolic syndrome
  • Phosphodiesterase-5

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine

Cite this

Maresca, L., D'Agostino, M., Castaldo, L., Vitelli, A., Mancini, M., Torella, G., ... Vigorito, C. (2013). Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors. Monaldi Archives for Chest Disease - Cardiac Series, 80(4), 177-183.

Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors. / Maresca, Luigi; D'Agostino, Mariantonietta; Castaldo, Luigi; Vitelli, Alessandra; Mancini, Maria; Torella, Giorgio; Lucci, Rosa; Albano, Giovanna; Del Forno, Domenico; Ferro, Matteo; Altieri, Vincenzo; Giallauria, Francesco; Vigorito, Carlo.

In: Monaldi Archives for Chest Disease - Cardiac Series, Vol. 80, No. 4, 01.12.2013, p. 177-183.

Research output: Contribution to journalArticle

Maresca, L, D'Agostino, M, Castaldo, L, Vitelli, A, Mancini, M, Torella, G, Lucci, R, Albano, G, Del Forno, D, Ferro, M, Altieri, V, Giallauria, F & Vigorito, C 2013, 'Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors', Monaldi Archives for Chest Disease - Cardiac Series, vol. 80, no. 4, pp. 177-183.
Maresca, Luigi ; D'Agostino, Mariantonietta ; Castaldo, Luigi ; Vitelli, Alessandra ; Mancini, Maria ; Torella, Giorgio ; Lucci, Rosa ; Albano, Giovanna ; Del Forno, Domenico ; Ferro, Matteo ; Altieri, Vincenzo ; Giallauria, Francesco ; Vigorito, Carlo. / Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors. In: Monaldi Archives for Chest Disease - Cardiac Series. 2013 ; Vol. 80, No. 4. pp. 177-183.
@article{b371bde11dff4c1f88c331bc8139fcb6,
title = "Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors",
abstract = "Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase- 5 (PDE-5) inhibitors. L. Maresca, M. D'Agostino, L. Castaldo, A. Vitelli, M. Mancini, G. Torella, R. Lucci, G. Albano, D. Del Forno, M. Ferro, V. Altieri, F. Giallauria, C. Vigorito. Introduction. Erectile dysfunction (ED) affects about 50{\%} of males aged 40-70 years old. ED shares with atherosclerotic disease several common risk factors; therefore, it may be considered a surrogate marker of atherosclerosis. Sincephosphodiesterase-5 inhibitors are well known pharmacologic agents capable of significant improvement in ED, we designed this study to evaluate whether exercise training is of added value in patients with ED who are already on PDE-5 inhibitors. Methods. We recruited 20 male patients affected by ED with metabolic syndrome.At baseline, all patients underwent Cardio-Pulmonary Exercise Testing (CPET) and the International Index of Erectile Function (IIEF) test.After the initial evaluation, patients were subdivided into two groups: tadalafil group (group T, n=10), who were maintained only on tadalafil therapy, and a tadalafil/exercise training group (T/E group, n=10)who continued tadalafil but in addition underwent a2-month structured exercise training program. Results. Basal anthropometric characteristics of study population showed no significant differences. Although bothgroups showed at 2 months an improvement of the IIEF score, thiswas more evident in the T/E group (T group: 11.2 vs 14.2, P=0.02; T/E group: 10.8 vs 20.1, P2peak) only in the T/E group patients (T group: 13.63±2.03 vs 14.24±2.98 mL/kg/min; P=0.521; T/E group: 13.41±2.97 vs 16.58±3.17 mL/kg/min; P=0.006). A significant correlation was found between the changes in VO2peak and the modifications in IIEF score (r=0.575; P=0.001). Conclusion. Exercise training in ED patients treated with PDE-5 inhibitors is of added valuesincefurther improves ED, as evaluated by IIEF score, and increases functional capacity.",
keywords = "Erectile dysfunction, Erectile dysfunction therapy, Exercise training, Metabolic syndrome, Phosphodiesterase-5",
author = "Luigi Maresca and Mariantonietta D'Agostino and Luigi Castaldo and Alessandra Vitelli and Maria Mancini and Giorgio Torella and Rosa Lucci and Giovanna Albano and {Del Forno}, Domenico and Matteo Ferro and Vincenzo Altieri and Francesco Giallauria and Carlo Vigorito",
year = "2013",
month = "12",
day = "1",
language = "English",
volume = "80",
pages = "177--183",
journal = "Monaldi Archives for Chest Disease",
issn = "1122-0643",
publisher = "Fondazione Salvatore Maugeri",
number = "4",

}

TY - JOUR

T1 - Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors

AU - Maresca, Luigi

AU - D'Agostino, Mariantonietta

AU - Castaldo, Luigi

AU - Vitelli, Alessandra

AU - Mancini, Maria

AU - Torella, Giorgio

AU - Lucci, Rosa

AU - Albano, Giovanna

AU - Del Forno, Domenico

AU - Ferro, Matteo

AU - Altieri, Vincenzo

AU - Giallauria, Francesco

AU - Vigorito, Carlo

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase- 5 (PDE-5) inhibitors. L. Maresca, M. D'Agostino, L. Castaldo, A. Vitelli, M. Mancini, G. Torella, R. Lucci, G. Albano, D. Del Forno, M. Ferro, V. Altieri, F. Giallauria, C. Vigorito. Introduction. Erectile dysfunction (ED) affects about 50% of males aged 40-70 years old. ED shares with atherosclerotic disease several common risk factors; therefore, it may be considered a surrogate marker of atherosclerosis. Sincephosphodiesterase-5 inhibitors are well known pharmacologic agents capable of significant improvement in ED, we designed this study to evaluate whether exercise training is of added value in patients with ED who are already on PDE-5 inhibitors. Methods. We recruited 20 male patients affected by ED with metabolic syndrome.At baseline, all patients underwent Cardio-Pulmonary Exercise Testing (CPET) and the International Index of Erectile Function (IIEF) test.After the initial evaluation, patients were subdivided into two groups: tadalafil group (group T, n=10), who were maintained only on tadalafil therapy, and a tadalafil/exercise training group (T/E group, n=10)who continued tadalafil but in addition underwent a2-month structured exercise training program. Results. Basal anthropometric characteristics of study population showed no significant differences. Although bothgroups showed at 2 months an improvement of the IIEF score, thiswas more evident in the T/E group (T group: 11.2 vs 14.2, P=0.02; T/E group: 10.8 vs 20.1, P2peak) only in the T/E group patients (T group: 13.63±2.03 vs 14.24±2.98 mL/kg/min; P=0.521; T/E group: 13.41±2.97 vs 16.58±3.17 mL/kg/min; P=0.006). A significant correlation was found between the changes in VO2peak and the modifications in IIEF score (r=0.575; P=0.001). Conclusion. Exercise training in ED patients treated with PDE-5 inhibitors is of added valuesincefurther improves ED, as evaluated by IIEF score, and increases functional capacity.

AB - Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase- 5 (PDE-5) inhibitors. L. Maresca, M. D'Agostino, L. Castaldo, A. Vitelli, M. Mancini, G. Torella, R. Lucci, G. Albano, D. Del Forno, M. Ferro, V. Altieri, F. Giallauria, C. Vigorito. Introduction. Erectile dysfunction (ED) affects about 50% of males aged 40-70 years old. ED shares with atherosclerotic disease several common risk factors; therefore, it may be considered a surrogate marker of atherosclerosis. Sincephosphodiesterase-5 inhibitors are well known pharmacologic agents capable of significant improvement in ED, we designed this study to evaluate whether exercise training is of added value in patients with ED who are already on PDE-5 inhibitors. Methods. We recruited 20 male patients affected by ED with metabolic syndrome.At baseline, all patients underwent Cardio-Pulmonary Exercise Testing (CPET) and the International Index of Erectile Function (IIEF) test.After the initial evaluation, patients were subdivided into two groups: tadalafil group (group T, n=10), who were maintained only on tadalafil therapy, and a tadalafil/exercise training group (T/E group, n=10)who continued tadalafil but in addition underwent a2-month structured exercise training program. Results. Basal anthropometric characteristics of study population showed no significant differences. Although bothgroups showed at 2 months an improvement of the IIEF score, thiswas more evident in the T/E group (T group: 11.2 vs 14.2, P=0.02; T/E group: 10.8 vs 20.1, P2peak) only in the T/E group patients (T group: 13.63±2.03 vs 14.24±2.98 mL/kg/min; P=0.521; T/E group: 13.41±2.97 vs 16.58±3.17 mL/kg/min; P=0.006). A significant correlation was found between the changes in VO2peak and the modifications in IIEF score (r=0.575; P=0.001). Conclusion. Exercise training in ED patients treated with PDE-5 inhibitors is of added valuesincefurther improves ED, as evaluated by IIEF score, and increases functional capacity.

KW - Erectile dysfunction

KW - Erectile dysfunction therapy

KW - Exercise training

KW - Metabolic syndrome

KW - Phosphodiesterase-5

UR - http://www.scopus.com/inward/record.url?scp=84937926755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937926755&partnerID=8YFLogxK

M3 - Article

VL - 80

SP - 177

EP - 183

JO - Monaldi Archives for Chest Disease

JF - Monaldi Archives for Chest Disease

SN - 1122-0643

IS - 4

ER -